6.6: Acute Stroke
Priority Medicines for Europe and the World
"A Public Health Approach to Innovation"
Background Paper
Acute Stroke
By Dr Eduardo Sabaté and Dr Sunil Wimalaratna
With appreciation to the WHO/CVD Unit and Drs Julien.Bogousslavsky, Patrik Michel, and
Cesare Fieschi for their comments.
7 October 2004
6.6-1
, 6.6: Acute Stroke
Table of Contents
Abbreviations .......................................................................................................................................... 3
Summary .................................................................................................................................................. 4
6.6.1 Introduction ................................................................................................................................ 5
6.6.2 Burden of stroke ......................................................................................................................... 8
6.6.3 Control strategy........................................................................................................................ 12
6.6.4 Major problem and challenges of stroke management: why does the disease burden
persist? ....................................................................................................................................... 14
6.6.5 Past and current research into pharmaceutical interventions for managing stroke ...... 15
6.6.6 What are the opportunities for research into new pharmaceutical interventions that
might fill the current gap and make a substantial difference? .......................................... 18
6.6.7 Conclusions............................................................................................................................... 20
6.6.8 References ................................................................................................................................. 21
6.6-2
, 6.6: Acute Stroke
Abbreviations
COPD: Chronic Obstructive Pulmonary LBW: low birth weight
Diseases LRI: Low Respiratory Infections
MRI: magnetic resonance imaging
CT: computerized tomography
NIHSS: National Institutes of Health Stroke
CVA: cerebrovascular accident
Scale
DALY: disability-adjusted life years
NINDS: National Institute of Neurologic
DWI: Diffusion-weighted imaging
Diseases Study
EU: European Union
ODD, other digestive diseases
EU10: European Union’s new accession
OID, other infectious diseases
countries.
OUI: other unintentional injuries
EU15: European Union with 15 countries
QALY: Quality-adjusted Life Years
EU25: European Union with 25 countries
rt-PA: recombinant tissue plasminogen
FDA: Food and Drug Administration
activator
HL, hearing loss, adult onset
TBLC, trachea, bronchus, lung cancers
IHD: Ischaemic Heart Disease
TIA: transient ischaemic attacks
6.6-3
Priority Medicines for Europe and the World
"A Public Health Approach to Innovation"
Background Paper
Acute Stroke
By Dr Eduardo Sabaté and Dr Sunil Wimalaratna
With appreciation to the WHO/CVD Unit and Drs Julien.Bogousslavsky, Patrik Michel, and
Cesare Fieschi for their comments.
7 October 2004
6.6-1
, 6.6: Acute Stroke
Table of Contents
Abbreviations .......................................................................................................................................... 3
Summary .................................................................................................................................................. 4
6.6.1 Introduction ................................................................................................................................ 5
6.6.2 Burden of stroke ......................................................................................................................... 8
6.6.3 Control strategy........................................................................................................................ 12
6.6.4 Major problem and challenges of stroke management: why does the disease burden
persist? ....................................................................................................................................... 14
6.6.5 Past and current research into pharmaceutical interventions for managing stroke ...... 15
6.6.6 What are the opportunities for research into new pharmaceutical interventions that
might fill the current gap and make a substantial difference? .......................................... 18
6.6.7 Conclusions............................................................................................................................... 20
6.6.8 References ................................................................................................................................. 21
6.6-2
, 6.6: Acute Stroke
Abbreviations
COPD: Chronic Obstructive Pulmonary LBW: low birth weight
Diseases LRI: Low Respiratory Infections
MRI: magnetic resonance imaging
CT: computerized tomography
NIHSS: National Institutes of Health Stroke
CVA: cerebrovascular accident
Scale
DALY: disability-adjusted life years
NINDS: National Institute of Neurologic
DWI: Diffusion-weighted imaging
Diseases Study
EU: European Union
ODD, other digestive diseases
EU10: European Union’s new accession
OID, other infectious diseases
countries.
OUI: other unintentional injuries
EU15: European Union with 15 countries
QALY: Quality-adjusted Life Years
EU25: European Union with 25 countries
rt-PA: recombinant tissue plasminogen
FDA: Food and Drug Administration
activator
HL, hearing loss, adult onset
TBLC, trachea, bronchus, lung cancers
IHD: Ischaemic Heart Disease
TIA: transient ischaemic attacks
6.6-3
